MiGenTra Egypt

MiGenTra Egypt stands as a pioneering R&D and manufacturing biopharmaceutical facility, uniquely positioned as the first of its kind in Egypt, Africa, and the Middle East. The company specializes in the intricate development and production of therapeutic recombinant proteins, addressing critical medical needs across several key areas. Its focus encompasses liver disease, thrombosis and haemostasis, infertility, oncology, and rheumatoid arthritis, aiming to deliver advanced treatment solutions. This strategic specialization underscores MiGenTra Egypt's commitment to advancing healthcare within its operational regions.

Operating with a dedicated team of 500-1,000 employees, MiGenTra Egypt generates an annual revenue of $48.6M. As a vital subsidiary of Minapharm, the company not only manufactures but also spearheads the process and clinical development of its biopharmaceutical pipeline candidates. This integrated approach allows for comprehensive oversight from research to market-ready products. Meet MiGenTra Egypt's team to gain insight into the expertise driving these complex operations and innovations. The facility's operational footprint is significant, contributing to the region's growing biopharmaceutical capabilities.

The overarching mission of MiGenTra Egypt is to ensure patients have access to innovative, affordable, and high-quality genetically engineered recombinant drugs. By establishing this advanced biopharmaceutical hub, the company significantly contributes to local and regional self-sufficiency in critical medicines. Its presence strengthens the healthcare ecosystem in Egypt, Africa, and the Middle East, fostering technological advancement and improving patient outcomes through cutting-edge biopharmaceutical solutions.